JP2023518830A5 - - Google Patents
Info
- Publication number
- JP2023518830A5 JP2023518830A5 JP2022557169A JP2022557169A JP2023518830A5 JP 2023518830 A5 JP2023518830 A5 JP 2023518830A5 JP 2022557169 A JP2022557169 A JP 2022557169A JP 2022557169 A JP2022557169 A JP 2022557169A JP 2023518830 A5 JP2023518830 A5 JP 2023518830A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutical composition
- pharmaceutically acceptable
- lrrk2
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025030446A JP2025078673A (ja) | 2020-03-21 | 2025-02-27 | インダゾール系化合物及び関連使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062992952P | 2020-03-21 | 2020-03-21 | |
| US62/992,952 | 2020-03-21 | ||
| PCT/US2021/023183 WO2021194879A1 (en) | 2020-03-21 | 2021-03-19 | Indazole based compounds and associated methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025030446A Division JP2025078673A (ja) | 2020-03-21 | 2025-02-27 | インダゾール系化合物及び関連使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023518830A JP2023518830A (ja) | 2023-05-08 |
| JP2023518830A5 true JP2023518830A5 (https=) | 2024-03-13 |
| JP7644139B2 JP7644139B2 (ja) | 2025-03-11 |
Family
ID=75539924
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022557169A Active JP7644139B2 (ja) | 2020-03-21 | 2021-03-19 | インダゾール系化合物及び関連使用方法 |
| JP2025030446A Pending JP2025078673A (ja) | 2020-03-21 | 2025-02-27 | インダゾール系化合物及び関連使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025030446A Pending JP2025078673A (ja) | 2020-03-21 | 2025-02-27 | インダゾール系化合物及び関連使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12053469B2 (https=) |
| EP (1) | EP4121422A1 (https=) |
| JP (2) | JP7644139B2 (https=) |
| KR (1) | KR20230004511A (https=) |
| CN (1) | CN115697990B (https=) |
| AU (1) | AU2021244180A1 (https=) |
| BR (1) | BR112022018909A2 (https=) |
| CA (1) | CA3172387A1 (https=) |
| CO (1) | CO2022014718A2 (https=) |
| IL (1) | IL296648A (https=) |
| MX (1) | MX2022011674A (https=) |
| WO (1) | WO2021194879A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10654809B2 (en) | 2016-06-10 | 2020-05-19 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| WO2019195609A2 (en) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| JP7644139B2 (ja) | 2020-03-21 | 2025-03-11 | アルヴィナス・オペレーションズ・インコーポレイテッド | インダゾール系化合物及び関連使用方法 |
| WO2021194878A1 (en) * | 2020-03-21 | 2021-09-30 | Arvinas Operations, Inc. | Selective modulators of mutant lrrk2 proteolysis and associated methods of use |
| CN117321046A (zh) * | 2021-03-19 | 2023-12-29 | 阿维纳斯企业公司 | 基于吲唑的化合物和相关使用方法 |
| JP2024512501A (ja) * | 2021-03-19 | 2024-03-19 | アルヴィナス・オペレーションズ・インコーポレイテッド | インダゾール系化合物及び関連使用方法 |
| CA3235512A1 (en) * | 2021-10-22 | 2023-04-27 | Xiaobao Yang | Crbn e3 ligase ligand compound, protein degrader developed based thereon and their applications |
| EP4276097A1 (en) | 2022-05-10 | 2023-11-15 | University Of Dundee | Aminopyrimidinyl derivatives for the treament of parkinson's disease |
| WO2024010818A2 (en) * | 2022-07-07 | 2024-01-11 | University Of Tennessee Research Foundation | Proteolysis targeting chimera (protac) of selective androgen receptor degrader (sard) compounds and methods of use thereof |
| WO2024054876A1 (en) * | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Leucine rich repeat kinase 2 (lrrk2) degrading compounds and associated methods of use |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| WO2024173646A1 (en) * | 2023-02-16 | 2024-08-22 | Innovo Therapeutics, Inc. | Cyclin-dependent kinase degrading compounds |
| WO2025056074A1 (zh) * | 2023-09-14 | 2025-03-20 | 中国科学院上海药物研究所 | 杂环基取代的吲唑酮类化合物、其制备方法、药物组合物及其应用 |
| TW202515874A (zh) | 2023-09-28 | 2025-04-16 | 美商亞文納營運公司 | 用於靶向降解富含白胺酸之重複激酶２（ｌｒｒｋ２）的基於苯并咪唑及苯并咪唑酮之ｐｒｏｔａｃ化合物 |
| WO2025123046A1 (en) | 2023-12-07 | 2025-06-12 | Arvinas Operations, Inc. | Synthesis of leucine-rich repeat kinase 2 modulators |
| CN120787222A (zh) * | 2024-02-04 | 2025-10-14 | 标新生物医药科技(上海)有限公司 | 基于取代的异吲哚啉酮新颖骨架化合物、含有其的双功能蛋白降解剂及它们的应用 |
| CN118344284A (zh) * | 2024-03-06 | 2024-07-16 | 杭州医学院 | 一种具有苯甲酰胺结构的化合物及其制备方法和应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| ES2577829T3 (es) | 2010-06-04 | 2016-07-19 | F. Hoffmann-La Roche Ag | Derivados de aminopirimidina como moduladores de la LRRK2 |
| KR102668696B1 (ko) | 2012-01-12 | 2024-05-29 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| WO2014134774A1 (en) | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| WO2014134776A1 (en) | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| US9718818B2 (en) | 2013-08-22 | 2017-08-01 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| RU2738833C9 (ru) | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| MX2019005007A (es) * | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| AU2018219292B2 (en) * | 2017-02-08 | 2024-09-26 | Dana-Farber Cancer Institute, Inc. | Tunable endogenous protein degradation with heterobifunctional compounds |
| WO2019060742A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc | AGENTS FOR DEGRADING PROTEINS AND USES THEREOF |
| IL302595A (en) | 2018-04-13 | 2023-07-01 | Arvinas Operations Inc | Servalon ligands and bifunctional compounds containing them |
| US20210261553A1 (en) | 2018-05-15 | 2021-08-26 | E-Scape Bio, Inc. | Fused tetrazoles as lrrk2 inhibitors |
| JP7297053B2 (ja) * | 2018-08-20 | 2023-06-23 | アルビナス・オペレーションズ・インコーポレイテッド | 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解 |
| US20210361774A1 (en) | 2018-10-16 | 2021-11-25 | Dana-Farber Cancer Institute, Inc. | Degraders of wild-type and mutant forms of lrrk2 |
| US20230219945A1 (en) | 2019-12-17 | 2023-07-13 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| JP7644139B2 (ja) | 2020-03-21 | 2025-03-11 | アルヴィナス・オペレーションズ・インコーポレイテッド | インダゾール系化合物及び関連使用方法 |
| WO2021194878A1 (en) * | 2020-03-21 | 2021-09-30 | Arvinas Operations, Inc. | Selective modulators of mutant lrrk2 proteolysis and associated methods of use |
| JP2024512501A (ja) * | 2021-03-19 | 2024-03-19 | アルヴィナス・オペレーションズ・インコーポレイテッド | インダゾール系化合物及び関連使用方法 |
-
2021
- 2021-03-19 JP JP2022557169A patent/JP7644139B2/ja active Active
- 2021-03-19 WO PCT/US2021/023183 patent/WO2021194879A1/en not_active Ceased
- 2021-03-19 CN CN202180035521.9A patent/CN115697990B/zh active Active
- 2021-03-19 KR KR1020227036283A patent/KR20230004511A/ko not_active Withdrawn
- 2021-03-19 US US17/207,325 patent/US12053469B2/en active Active
- 2021-03-19 BR BR112022018909A patent/BR112022018909A2/pt not_active Application Discontinuation
- 2021-03-19 AU AU2021244180A patent/AU2021244180A1/en not_active Abandoned
- 2021-03-19 EP EP21719336.6A patent/EP4121422A1/en active Pending
- 2021-03-19 IL IL296648A patent/IL296648A/en unknown
- 2021-03-19 CA CA3172387A patent/CA3172387A1/en active Pending
- 2021-03-19 MX MX2022011674A patent/MX2022011674A/es unknown
-
2022
- 2022-10-18 CO CONC2022/0014718A patent/CO2022014718A2/es unknown
-
2024
- 2024-08-05 US US18/794,292 patent/US20250114356A1/en active Pending
-
2025
- 2025-02-27 JP JP2025030446A patent/JP2025078673A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023518830A5 (https=) | ||
| JP2021001196A5 (https=) | ||
| JP2020183410A5 (https=) | ||
| JP2024156774A5 (https=) | ||
| JP2020512337A5 (https=) | ||
| JP2006516570A5 (https=) | ||
| JP2012507566A5 (https=) | ||
| JP2020508338A5 (https=) | ||
| JP2020505423A5 (https=) | ||
| JP2024540183A5 (https=) | ||
| JP2017537948A5 (https=) | ||
| JP2007091758A5 (https=) | ||
| JP2021152008A5 (https=) | ||
| JP2008540672A (ja) | 病状に起因する性的機能不全の治療方法 | |
| JP2020520359A5 (https=) | ||
| JP2008516004A5 (https=) | ||
| JP2022515406A5 (https=) | ||
| JP2023540506A5 (https=) | ||
| JP2008524218A5 (https=) | ||
| JP2021534227A5 (https=) | ||
| US20220193106A1 (en) | Nucleobase analogue derivatives and their applications | |
| ME01246B (me) | So 4[[4-[[4-(2-cijanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrila | |
| JP2013544271A5 (https=) | ||
| JP2018507207A5 (https=) | ||
| JP2019085364A5 (https=) |